
This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
To own SiriusPoint, you need to believe it can turn disciplined underwriting and a less volatile business mix into durable profitability while managing catastrophe and reserve risks. The latest results reinforce that story in the near term, but the most important catalyst now is whether earnings quality holds up as the company leans further into specialty and Accident & Health, while the biggest risk remains that MGA-driven growth or catastrophe losses could reintroduce earnings volatility.
The Board’s plan to consider a new share repurchase program is especially relevant here, because it sits on top of stronger reported earnings and a 28% increase in diluted book value per share. If repurchases proceed, they could amplify the impact of any future swings in underwriting or investment results, making the sustainability of current performance and the resilience of the portfolio mix even more important to watch.
Yet behind these strong numbers, investors should be aware that growing dependence on newer MGA partnerships could still...
Read the full narrative on SiriusPoint (it's free!)
SiriusPoint's narrative projects $3.5 billion revenue and $402.8 million earnings by 2028.
Uncover how SiriusPoint's forecasts yield a $27.50 fair value, a 28% upside to its current price.
Some of the most optimistic analysts were already assuming revenue of about US$3.6 billion and earnings near US$398 million by 2028, so this earnings beat may either support that upbeat view or prompt a rethink of how much catastrophe and MGA risk you are comfortable with.
Explore 2 other fair value estimates on SiriusPoint - why the stock might be worth as much as 61% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com